Arcus Biosciences/RCUS

$19.37

-4.01%
-
1D1W1MYTD1YMAX

About Arcus Biosciences

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. It is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. It is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The Company's investigational products also include etrumadenant and quemliclustat.

Ticker

RCUS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Terry Rosen

Employees

577

Headquarters

Hayward, United States

RCUS Metrics

BasicAdvanced
$1.79B
Market cap
-
P/E ratio
-$4.15
EPS
0.81
Beta
-
Dividend rate

What the Analysts think about RCUS

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
103.41% upside
High $70.00
Low $25.00
$19.37
Current price
$39.40
Average price target

RCUS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-261.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$31M
-3.13%
Net income
$-81M
14.08%
Profit margin
-261.29%
17.77%

RCUS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.72%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$1.09
-$1.04
-$0.94
-
Expected
-$1.16
-$1.10
-$1.13
-$0.93
Surprise
-6.3%
-5.33%
-16.72%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Arcus Biosciences stock

Buy or sell Arcus Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing